I hope not using the DSMB's recommendation to look at all cause mortality at 42 days doesn't end up affecting overall efficacy. I wonder if they saw a bunch of patients in the placebo arm sinking fast and thought the mortality percent would be significant higher(14 days more)? But if that were the case, they might have been obligated to stop the trial due to benefit in the treatment arm.